CHMP recommends IDegLira (now Xultophy) for treatment of Type 2 Diabetes - Novo Nordisk
Novo Nordisk announced that the Committee for Medicinal Products for Human Use (CHMP) under the European Medicines Agency (EMA) adopted a positive opinion, recommending marketing authorisation for Xultophy for the treatment of Type 2 Diabetes mellitus in adults. Xultophy is the intended brand name for IDegLira, the first once-daily single injection combination of Tresiba (insulin degludec) and Victoza (liraglutide), developed for the treatment of Type 2 Diabetes.
The CHMP positive opinion recommends that Xultophy will be indicated for the treatment of adults with Type 2 Diabetes mellitus to improve glycaemic control in combination with oral glucose-lowering medicinal products when these alone or combined with basal insulin do not provide adequate glycaemic control.
Learning Zones
The Learning Zones are an educational resource for healthcare professionals that provide medical information on the epidemiology, pathophysiology and burden of disease, as well as diagnostic techniques and treatment regimens.